becton dickinson co nyse qqq
bd intervent busi pois rebound
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
becton dickinson certainli keen abandon predict
compani monik surpris investor commun five
year ago first major acquisit oper histori
bd doubl carefus deal size purchas
 bard big fan bard believ addit
higher-growth busi along reinvigor perform
bd legaci busi push compani
organ revenu growth improv may seem
particularli impress nonetheless sizabl jump
compani compet product area histor
experienc growth broader medic sector bd
product pipelin potenti expand
overal size market posit compani full-suit
product solut vendor
essenti natur bd medic product given
compani ampl cash flow reinvest bd made
consciou effort deploy capit bolster offer
area diabet inject bioscienc compani
also built massiv presenc emerg market
distribut manufactur network unparallel med
tech world return intern invest becom
evid form improv organ growth compani
increasingli turn acquisit
acquisit carefus first sign bd depart
century-old strategi bolt-on acquisit
bard deal move compani even comfort zone
bard brought challeng oper area competit
deep-pocket research develop commit
complementari opportun bd product maxim
bard potenti go challeng said
believ bd continu allow bard autonomi particularli
pertain spend area peripher arteri
diseas give us confid compani postmerg
goal revenu growth synergi line
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
becton dickinson world largest manufactur distributor
medic surgic product needl syring sharps-dispos
unit compani also manufactur diagnost instrument reagent
well flow cytometri cell-imag system bd intervent
larg former bard busi account revenu
revenu account compani busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
rais fair valu estim per share
roll model updat long-term
forecast compani
bard brought lead product portfolio strong
engin onu bd maintain posit
signific integr risk play although
give bd benefit doubt model growth
bard segment next five year along
medic devic busi recent increas
growth rate across board larg unchang
sever driver behind recent revis growth
forecast first core medic busi see
effect signific invest
firm pipelin strongest long time
origin bd product suit carefus portfolio
medic dispens pump expand
firm launch innov product across spectrum
firm also expand presenc informat
histor
interconnect import pillar bd new strategi
aim control larger portion care
continuum diseas manag particularli area like
diabet bd alway strong attract
opportun develop world emerg
recent rais forecast bd lifesci
diagnost segment still face challeng tripath
busi compani lack scale product
breadth larger player made invest
higher-growth area mainli molecular diagnost
autom expand assay portfolio bd max
schedul launch high-volum molecular system
next year make greater inroad
bd emphasi profit allow expand
oper margin despit on-going price pressur raw
materi inflat although incorpor sizabl
margin boost current level forecast -- less
basi point per year believ compani
abl extract oper synergi carefus
histor rang bd plausibl scenario outcom
fairli tight due predict natur
medic divis cash flow key driver bull
bear scenario firm revenu growth abil
success integr carefus particular bard
rang revenu growth outcom still fairli tight
compound annual five-year growth
bull bear scenario respect howev
see volatil futur cash flow given
uncertainti surround bd abil integr
deal unpreced size best-cas
scenario fair valu estim bd per share
foundat bd moat manufactur scale
basic surgic product segment account
half compani busi compani
largest manufactur needles/syring competit
match bd scale make compet price
difficult said compani entir price-sett
busi commoditylik price
increas primarili achiev product mix
decreas matur line off-set higher price new
product introduct bd diagnost busi squar
narrow-moat bucket robust instal base
respons steadi recur revenu provid
switch cost defenc new entrant howev
compani assay lack signific differenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
particular brand devic rare switch thank
retrain cost well product process familiar
compani like carefus larg instal base
devic enjoy low custom turnov stream
recur revenu associ dispos long
oper life devic
bard dug narrow moat divers portfolio
differenti product patent protect
innov addit manag done credibl
job ad new product includ new technolog
requir market develop expand wide
rang product primarili variou acquisit
firm well posit provid hospit custom
group purchas organ one-stop shop
prospect bundl deal compani abil
make meaning innov key product
foley cathet allow firm stave price
pressur maintain presenc equip shelf
bard solidifi narrow moat relationship
practition vascular surgic urolog
oncolog area tie bard seek cultiv
physician prefer product
compani busi less presenc weaker
diagnost bioscienc area face mani
challeng warrant wide econom moat
carefus busi oligopoli matur domest
market certain would abl deploy
current tactic emerg market bd attempt
expand presenc higher-price-point product
suscept capital-spend fluctuat
develop world less pronounc emerg
market particularli carefus brand
cachet initi barrier entri rather low
bard critic variabl bd abil
success navig challeng integr bard
innov aggress natur bd conserv
reliant continu innov off-set price pressur
age portfolio bioscienc segment
would also like receiv narrow moat rate firm
hold lead posit flow cytomet invest
heavili expand presenc broader cell therapi
market still lack breadth capabl
carefus narrow moat stem high product
switch cost substanti barrier entri deriv
larg portion revenu product
market leader intraven infus pump
respir ventil
infection-control product carefus maintain
number-on market posit mani product
categori especi infus pump medication-dispens
equip estim hold global
share respect infus market particular
rel oligopoli carefus baxter hospira
braun control market new smaller
entrant hard time contend
establish player scale breadth product offer
product familiar hospit familiar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
structur bd compet area
histor virtual zero presenc certain
stage moat benefit presenc
bard portfolio product
view bd moat trend stabl compani
manufactur infrastructur surgic busi
sizabl hurdl potenti new entrant competit
fairli intens among exist industri particip
primarili commoditis natur mani
firm product especi emerg market
compani inabl consist rais price even line
inflat testament industri tough
competit dynam growth compani
manufactur infrastructur particularli outsid
strengthen scale advantag view
overal competit advantag stabl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
obard brought lead peripher arteri diseas
franchis signific market growth opportun
odevelop market fulli convert safeti
mandat convert place eu bd
abil expand mature-market safeti
obd max enjoy strong adopt
test menu grow platform continu
ogrowth compani hospit consum
capit equip product line like remain
weak healthcar provid remain cautiou
cash deploy
oth paclitaxel issu materi setback
compani drug-coat balloon franchis
uncertainti around futur product area
obd may experi price issu emerg
market particularli commodit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
bd leverag financ bard acquisit given
ampl stabl cash flow model compani
reduc debt load commenc buy-back program
five year financ billion came form
convert prefer stock mandatori convers
prefer stock convert
bd surgic product commoditylik make
differenti virtual non-existent forc firm
compet price field diagnost bioscienc
bd number rival abbott roch
possess greater market reach larger research
develop budget academ govern
spend environ unit state
europ may remain constrain long period
neg affect demand firm research
instrument bard acquisit challeng
integr much valu deal stem sale
oper synergi well compani abil
retain key bard personnel innov cultur
peripher busi experienc recent setback
due paclitaxel issu drug-coat balloon
compani total exposur product line materi
enough influenc overal uncertainti rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
ceo/chairman board/
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
compani execut among best industri
term capit alloc view assign bd
exemplari stewardship rate year firm
focus return invest capit wise capit
deploy limit growth acquisit
run major oper mishap
compani success record speak highli
longev bd strong return capit particularli
remark given half firm busi belong
manag appear understand take
basic medic devic
invest go steadili expans
manufactur footprint solidifi scale advantag
competit compani manag expand
presenc basic medic devic maintain robust
return competitor often exit arena
histor bd resist temptat sizabl
acquisit instead focus fill small product gap
rather market share grab carefus bard
deal departur histor strategi
manag team far deliv promis
particularli impress abil extract
cost synergi low-hang fruit consid
carefus rel bloat cost structur also
manag step far increas growth
core carefus busi histor level
requir bolster exist portfolio
meaning invest leverag
infrastructur deliv carefus product geographi
previous lack capac new long-term
growth target incorpor elev perform
integr bard challeng task consid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
bard portfolio product requir higher capit intens
cautious optimist bd retain bard
key personnel leav cultur intact
result bard remain top-tier player devic space
firm new leadership structur includ number
key bard execut sever segment
post-acquisit bd led ex-bard manag
critic maintain innov cultur
allow bard becom one best-run medic devic
come govern practic compani
shareholder-friendli polici place consid
gener success align corpor perform
execut pay top manag also requir
receiv portion total pay compani stock
disclosur detail compani
histor avoid pollut financi statement
non-gaap adjust though polici chang
larg amort expens hit incom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
bd fourth quarter modest fair valu estim
increas time valu money
becton dickinson fourth-quart result line
estim compani guidanc includ drug-
coat balloon-rel headwind weak
china medic product segment neg currenc
adjust factor compani revenu
earn project line forecast
plan rais fair valu estim modestli
time valu money maintain narrow moat rate
segment compani perform balanc
medic life scienc intervent
last segment includ reduct
usag drug-coat balloon expect
geographi unit state intern
emerg market deliv organ
china saw slower-than-expect growth quarter
bd discuss price pressur china
commodit product line driven tender process
sever region wonder long bd
maintain torrid china growth particularli much
busi region rather basic medic
surgic instrument price develop
come shock us bd expect continu price
pressur suggest aberr
someth consid busi usual go
forward note china bd medic surgic
product line still expect grow doubl
digit
due currenc remaind due
oper improv bd guidanc
includ anoth basi point margin expans
achiev
off-set neg news below-the-kne product
becton dickinson third-quart updat upbeat right
compani commentari approv setback
below-the-kne btk product combin
seemingli longer recoveri drug-coat balloon
dcb franchis growth peripher busi
like return prepaclitaxel-issu level
earliest adjust forecast peripher
segment downward although given altogeth dcb
relat product compris bd total sale
effect isnt like materi thu maintain fair
valu estim narrow-moat rate
segment compani perform decent
medic life scienc peripher
latter deliv result includ reduct
usag dcb compani note previous
expect on-going weak dcb
remaind year suggest dcb
franchis like follow path coronari stent
took sever year normal bd would like see
fda take stronger posit regard clinic benefit
dcb rel risk absenc clearer
recommend doctor like continu take
cautiou approach btk setback bit surpris
us although compani suggest fda
reject wasnt outright death sentenc btk
devic bd didnt provid detail fda
ask term data state competit reason
given origin paclitaxel panel focu longer-
term data two year plu six-month data
compani submit btk product probabl
long enough dcb btk arent critic
valuat bd given repres sale
product among excit aspect
bard pipelin re-affirmed guidanc line
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
estim
bd manag cost base effect sever
question call regard overal invest level
peripher busi activ measur
undertaken stage
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
becton dickinson co nyse qqq
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
